21:16 , Nov 8, 2016 |  BC Week In Review  |  Clinical News

SynGEM: Ph I started

Mucosis began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate 2 intranasal doses of SynGEM in 48 healthy adult volunteers. Mucosis B.V. , Groningen, the Netherlands  Product: SynGEM   Business: Infectious  Molecular target: NA ...
08:00 , Nov 13, 2014 |  BC Innovations  |  Cover Story

Boosting adjuvants

For all the talk of new vaccines, not much attention has been paid to the need for better adjuvants, which have remained stuck on alum-based products for decades. The NIH is committing up to $70...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Financial News

Mucosis financial update

Mucosis secured a €5 million ($6.8 million) line of credit from the Dutch Ministry of Economic Affairs' Netherlands Enterprise Agency. Mucosis declined to disclose the interest rate but did say the agency's credit lines "generally...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Financial News

Mucosis completes venture financing

Mucosis B.V. , Groningen, the Netherlands   Business: Infectious   Date completed: 4/15/14   Type: Venture financing   Raised: €5 million ($6.9 million)   Investors: Changchun BCHT Biotechnology; BioGeneration Ventures; MedSciences Capital; NV NOM; Utrecht...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

Changchun BCHT, Mucosis deal

Changchun received exclusive, Chinese rights and non-exclusive rights in other undisclosed Asian countries to Mucosis' SynGEM respiratory syncytial virus (RSV) vaccine and Mimopath technology for undisclosed disease targets. Changchun will make an equity investment in...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Mucosis, J&J deal

Mucosis granted Crucell N.V. rights to use Mimopath technology to develop vaccines against infectious diseases. The technology is based on the Lactococcus lactis bacteria, which Mucosis formulates into non-living bacterium-like particles (BLPs) that can be...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Company News

ExpreS2ion, Mucosis, University of Copenhagen infectious news

The partners received a Eureka-Eurostarts grant worth over €1 million ($1.3 million) to fund preclinical development of a placental malaria vaccine to prevent infection in women in high-risk areas. ExpreS2ion will provide its ExpreS2 recombinant...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Company News

Mucosis management update

Mucosis B.V. , Groningen, the Netherlands   Business: Infectious   Transitioned: Thomas Johnston to CEO from CBO; he succeeds Govert Schouten, who departed  ...
01:28 , Sep 18, 2012 |  BC Extra  |  Company News

Mucosis names Johnston CEO

Mucosis B.V. (Groningen, the Netherlands) named Thomas Johnston as CEO. He succeeds Govert Schouten, who is departing. Johnston, who was CBO at Mucosis, said the CBO position would remain open and that he would assume...
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

FluGEM: Phase I data

A single-blind, Dutch Phase I trial in 60 healthy volunteers aged 18-49 showed that intranasal FluGEM was well tolerated with a rate of overall adverse events comparable to that of standard trivalent split influenza antigen....